<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="940">
  <stage>Registered</stage>
  <submitdate>20/10/2005</submitdate>
  <approvaldate>20/10/2005</approvaldate>
  <nctid>NCT00243178</nctid>
  <trial_identification>
    <studytitle>Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)</studytitle>
    <scientifictitle>A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EFC4912 W</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atrial Fibrillation</healthcondition>
    <healthcondition>Vascular Risk</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - clopidogrel (SR25990C)

Treatment: drugs: clopidogrel (SR25990C)
75 mg once daily in combination with aspirin

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome:time to the first occurrence of stroke, non-CNS systemic embolism, myocardial infarction or vascular death</outcome>
      <timepoint>during approximately three years of follow-up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcomes: major hemorrhage, total mortality and stroke.</outcome>
      <timepoint>during approximately three years of follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Evidence of atrial fibrillation either on one current Electrocardiogram (ECG) or on
             two ECG recorded at two weeks a part during 6 months prior to study enrollment.

          -  Evidence of high risk of vascular events: at least one of the following risk criteria
             must be present:

               -  are 75 years or greater;

               -  on treatment for systemic hypertension;

               -  prior stroke, TIA, or non-CNS systemic embolus;

               -  left ventricular dysfunction with left ventricular ejection fraction (EF)
                  estimated by echocardiogram or angiogram (radionuclide or contrast) to be &lt; 45%;

               -  peripheral vascular disease (previous peripheral artery revascularization, limb
                  and foot amputation, or the combination of current intermittent claudication and
                  ankle arm systolic blood pressure ratio &lt; 0.9);

               -  age 55 to 74 years; AND

               -  either diabetes mellitus requiring drug therapy, or documented previous
                  myocardial infarction, or documented coronary artery disease.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients will be excluded from ACTIVE if any of the following are present :

               -  requirement for clopidogrel (such as recent coronary stent procedure);

               -  requirement for oral anticoagulant (such as prosthetic mechanical heart valve);

               -  prior intolerance to ASA or clopidogrel;

               -  documented peptic ulcer disease within the previous 6 months;

               -  prior intracerebral hemorrhage;

               -  significant thrombocytopenia; (platelet count &lt; 50 x 10(9)/L);

               -  psychosocial reason making study participation impractical;

               -  geographic reason making study participation impractical;

               -  ongoing alcohol abuse;

               -  mitral stenosis;

               -  pregnant or nursing woman or woman of child bearing potential and not on
                  effective birth control for at least one month prior to start of study or not
                  willing to continue on birth control for duration of study;

               -  severe comorbid condition such that the patient is not expected to survive 6
                  months;

               -  patient currently receiving an investigational pharmacologic agent; OR

               -  requirement for chronic (&gt; 3 months) non-COX-2 inhibitor NSAID therapy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>6706</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2005</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Sanofi-Aventis Administrative Office - Macquarie Park</hospital>
    <postcode> - Macquarie Park</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Diegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Laval</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Horsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Causeway Bay</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Natanya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Gouda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Lysaker</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto Salvo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Bromma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Guildford Surrey</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bristol-Myers Squibb</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if the combination of Clopidogrel 75mg once daily
      (od) plus aspirin at 100mg daily (recommended dose) is as effective as oral anticoagulation
      therapy with a lower risk of bleeding in patients with atrial fibrillation associated with at
      least one major cardiovascular risk factor.Primary objectives :The combination of clopidogrel
      plus aspirin compared to adjusted dose (INR between 2.0 and 3.3) oral anticoagulation (a
      vitamin K antagonist) will result in the same risk of the composite outcome of stroke,
      non-CNS systemic embolism, myocardial infarction or vascular death in patients with atrial
      fibrillation.The secondary objective is to establish whether or not aspirin plus clopidogrel
      has a lower risk of hemorrhage than standard anticoagulation therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00243178</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Salim YUSUF, Prof.</name>
      <address>Hamilton Health Sciences Corporation</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>